JP2013537891A5 - - Google Patents

Download PDF

Info

Publication number
JP2013537891A5
JP2013537891A5 JP2013528384A JP2013528384A JP2013537891A5 JP 2013537891 A5 JP2013537891 A5 JP 2013537891A5 JP 2013528384 A JP2013528384 A JP 2013528384A JP 2013528384 A JP2013528384 A JP 2013528384A JP 2013537891 A5 JP2013537891 A5 JP 2013537891A5
Authority
JP
Japan
Prior art keywords
patent document
composition
cyclodextrins
aspirin
drugs
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013528384A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013537891A (ja
JP5890951B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2011/051386 external-priority patent/WO2012037117A1/en
Publication of JP2013537891A publication Critical patent/JP2013537891A/ja
Publication of JP2013537891A5 publication Critical patent/JP2013537891A5/ja
Application granted granted Critical
Publication of JP5890951B2 publication Critical patent/JP5890951B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013528384A 2010-09-13 2011-09-13 不快味マスキング剤を有する水性薬物送達システム Expired - Fee Related JP5890951B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US38209810P 2010-09-13 2010-09-13
US61/382,098 2010-09-13
PCT/US2011/051386 WO2012037117A1 (en) 2010-09-13 2011-09-13 Aqueous drug delivery system comprising off - flavor masking agent
US13/231,150 US9018193B2 (en) 2010-09-13 2011-09-13 Aqueous drug delivery system
US13/231,150 2011-09-13

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016029886A Division JP6263699B2 (ja) 2010-09-13 2016-02-19 不快味マスキング剤を有する水性薬物送達システム

Publications (3)

Publication Number Publication Date
JP2013537891A JP2013537891A (ja) 2013-10-07
JP2013537891A5 true JP2013537891A5 (enExample) 2014-11-06
JP5890951B2 JP5890951B2 (ja) 2016-03-22

Family

ID=44674918

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2013528384A Expired - Fee Related JP5890951B2 (ja) 2010-09-13 2011-09-13 不快味マスキング剤を有する水性薬物送達システム
JP2016029886A Expired - Fee Related JP6263699B2 (ja) 2010-09-13 2016-02-19 不快味マスキング剤を有する水性薬物送達システム

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2016029886A Expired - Fee Related JP6263699B2 (ja) 2010-09-13 2016-02-19 不快味マスキング剤を有する水性薬物送達システム

Country Status (15)

Country Link
US (4) US9018193B2 (enExample)
EP (2) EP2616046B1 (enExample)
JP (2) JP5890951B2 (enExample)
KR (1) KR20140007798A (enExample)
CN (1) CN103209684A (enExample)
AU (1) AU2011302293B2 (enExample)
BR (1) BR112013005987A2 (enExample)
CA (1) CA2811202A1 (enExample)
IL (1) IL225149B (enExample)
MY (1) MY162175A (enExample)
NZ (1) NZ608239A (enExample)
PH (1) PH12013500477A1 (enExample)
RU (1) RU2013116336A (enExample)
SG (2) SG10201507554RA (enExample)
WO (1) WO2012037117A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150328246A1 (en) * 2014-05-16 2015-11-19 Vivus, Inc. Orally administratable formulations for the controlled release of a pharmacologically active agent
US11623008B2 (en) * 2014-08-20 2023-04-11 Professional Compounding Centers Of America Excipient compositions for mucoadhesive pharmaceutical compositions including a synergistic combination of amylopectin, pullulan, hyaluronic acid, and xyloglucan
EP3230256B1 (en) * 2014-12-09 2019-11-13 Ezekiel Golan Alcoholic beverage substitutes
EP3230255B1 (en) 2014-12-09 2020-03-18 Ezekiel Golan Binge behavior regulators
KR102055490B1 (ko) * 2015-04-07 2019-12-12 닛산 가가쿠 가부시키가이샤 액체 배지 조성물의 제조 방법, 및 이의 제조 장치 및 키트
US10493083B2 (en) 2015-10-30 2019-12-03 Cmp Development Llc Spironolactone aqueous compositions
WO2018048779A1 (en) * 2016-09-06 2018-03-15 Children's Medical Center Corporation Topical trpv1 antagonists and methods and compositions thereof
JP7181185B2 (ja) * 2016-09-16 2022-11-30 サイデックス・ファーマシューティカルズ・インコーポレイテッド アセトアミノフェンおよびスルホアルキルエーテルシクロデキストリンを含む製剤
CN111587106A (zh) * 2018-01-15 2020-08-25 西雅图咖米公司 半固态抗组胺组合物及其制备和使用方法
US10828286B2 (en) * 2018-05-24 2020-11-10 Gm Pharmaceuticals, Inc. Niacin and berberine compositions and methods of use thereof
CA3104568A1 (fr) 2018-06-29 2020-01-02 Roquette Freres Melange de molecules d'hydroxypropyl-.beta.-cyclodextrine et son procede de preparation
JP2020019731A (ja) * 2018-07-31 2020-02-06 日本食品化工株式会社 アムロジピンベシル酸塩の苦味抑制剤
JP6711875B2 (ja) * 2018-08-29 2020-06-17 日本食品化工株式会社 マクロライド化合物の苦味抑制剤
US20210401017A1 (en) * 2020-12-11 2021-12-30 Jiangnan University Preparation Method of Starch-based Double Emulsion Embedding Fat-soluble Functional Factors
US11452690B1 (en) * 2021-01-27 2022-09-27 ECI Pharmaceuticals, LLC Oral liquid compositions comprising amlodipine besylate and methods of using the same
GR1010732B (el) * 2023-06-02 2024-07-25 Ιουλια Κλεωνος Τσετη Φαρμακευτικη συνθεση ιβουπροφαινης και παρακεταμολης για απο του στοματος χορηγηση
CN119185191A (zh) * 2024-09-12 2024-12-27 广东心宝药业科技有限公司 一种口服液药物口感的控制方法及系统

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2588189B1 (fr) 1985-10-03 1988-12-02 Merck Sharp & Dohme Composition pharmaceutique de type a transition de phase liquide-gel
FR2647343B1 (fr) * 1989-05-24 1994-05-06 Rhone Poulenc Sante Nouvelle forme pharmaceutique poreuse et sa preparation
GB9226391D0 (en) 1992-12-18 1993-02-10 Cpc International Inc Xanthan gelling agents
US5362860A (en) 1993-02-01 1994-11-08 Warner-Lambert Company Neutral stabilization complex for CI-979 HCl, a cognition activator
FR2704146B1 (fr) 1993-04-19 1995-07-13 Cripdom Microcapsules d'acide acétylsalicylique à libération contrôlée.
US5651980A (en) 1994-04-15 1997-07-29 Biohybrid Technologies, Inc. Methods of use of uncoated gel particles
US6319535B1 (en) 1995-11-28 2001-11-20 Laurence J. Shaw Confections that “swim” in a carbonated beverage
HUP9904115A3 (en) 1996-10-09 2001-01-29 Givaudan Roure Int Process for preparing beads as food additive
CA2273206A1 (en) 1996-11-29 1998-06-04 Monsanto Company Lubricious self-standing (intact) gel for oral delivery of biologically-active ingredients
US5776431A (en) 1997-03-26 1998-07-07 Galat; Alexander Water-soluble aspirin composition
DK0974366T3 (da) 1997-03-28 2007-01-29 Eisai Co Ltd Orale, farmaceutiske præparater med nedsat bitterhed ved maskering
BE1011251A3 (fr) 1997-07-03 1999-06-01 Ucb Sa Compositions pharmaceutiques administrables par voie orale, comprenant une substance active et une cyclodextrine.
US6306843B1 (en) 1997-07-15 2001-10-23 Walter Burghart Method for producing stable acetylsalicylic acid solutions
AU744328B2 (en) 1997-10-31 2002-02-21 Cp Kelco Aps Controlled release compositions comprising gellan gum gels
US6572898B2 (en) 1999-05-21 2003-06-03 Pts Labs Llc Electrolyte gels for maintaining hydration and rehydration
SK282717B6 (sk) 2000-03-10 2002-11-06 �Stav Experiment�Lnej Farmakol�Gie Sav Spôsob prípravy ultravysokomolekulových hyalurónanov
CN1476300B (zh) 2000-10-16 2013-11-06 百事可乐公司 加钙饮料及其生产方法
US7141555B2 (en) 2000-12-19 2006-11-28 Cephalon, Inc. Modafinil compound and cyclodextrin mixtures
US7494669B2 (en) 2001-02-28 2009-02-24 Carrington Laboratories, Inc. Delivery of physiological agents with in-situ gels comprising anionic polysaccharides
MXPA04008173A (es) * 2002-02-22 2004-11-26 Pharmacia Corp Formulaciones de farmaco antibiotico oftalmico que contienen un compuesto de ciclodextrina y cloruro de cetil piridinio.
US20090215735A1 (en) * 2002-02-25 2009-08-27 Alcon, Inc. Topical solution formulations containing a corticosteroid and a cyclodextrin
WO2003074086A1 (fr) 2002-03-04 2003-09-12 Medrx Co., Ltd. Matrice liquide a transfert de phase in vivo, et preparations liquides orales
WO2004009053A2 (en) 2002-07-19 2004-01-29 Vitalstate Canada Ltd. Oral delivery system containing a gel matrix and liposomes
ES2355723T3 (es) 2002-09-11 2011-03-30 Elan Pharma International Limited Composiciones de agente activo en nanopartículas estabilizadas en gel.
US20060018972A1 (en) 2002-11-26 2006-01-26 Upm Pharmaceuticals, Inc. Aqueous sustained-release drug delivery system for highly water-soluble electrolytic drugs
US7160565B2 (en) 2003-03-31 2007-01-09 Breakthru Products, Llc Hydration beverage and method of delivering nutrients
CN100548381C (zh) 2003-09-12 2009-10-14 株式会社龙角散 能掩盖苦味的粒状凝胶饮料
CA2542755A1 (en) 2003-10-17 2005-04-28 Medrx Co., Ltd. Biguanide drug-containing jelly preparation
IL160095A0 (en) 2004-01-28 2004-06-20 Yissum Res Dev Co Formulations for poorly soluble drugs
WO2006004574A2 (en) * 2004-02-19 2006-01-12 Abbott Laboratories Method for using gamma cyclodextrin to control blood glucose and insulin secretion
EP2258349B1 (en) 2004-05-11 2014-07-16 Egalet Ltd. Swellable dosage form comprising gellan gum
WO2005115341A2 (en) 2004-05-27 2005-12-08 Advanced Bionutrition Corporation Microparticles for oral delivery
CA2574602A1 (en) 2004-07-22 2006-02-02 Pfizer Products Inc. Taste masking formulation comprising the drug in a dissolution-retarded form and/or cyclodextrin in a dissolution-enhanced form
US20070092561A1 (en) 2005-06-24 2007-04-26 Don Milne Water-Soluble Aspirin Composition
US8715731B2 (en) 2006-03-22 2014-05-06 Isp Investments Inc. Process of reducing the bitter taste of water soluble actives by co-grinding the active with β cyclodextrin
PT103476B (pt) 2006-05-10 2008-09-19 Univ De Coimbra Processo de produção e isolamento de micro- e nanopartículas poliméricas contendo macromoléculas de natureza hidrofílica e termolábil
JP2009542895A (ja) 2006-07-06 2009-12-03 アボツト・レスピラトリー・エル・エル・シー 酷使に耐える超多孔質ヒドロゲル
US20100015227A1 (en) 2006-07-14 2010-01-21 Amos Nussinovitch Dried electrified hydrocolloid gels having unique structure and porosity
WO2008012329A2 (en) 2006-07-28 2008-01-31 V. Mane Fils Seamless capsules containing high amounts of polyunsaturated fatty acids and a flavouring component
GB0616794D0 (en) * 2006-08-24 2006-10-04 Arrow Int Ltd Solid dosage form
JP5205909B2 (ja) * 2006-10-18 2013-06-05 大正製薬株式会社 粘膜適用液剤
JP5048398B2 (ja) * 2007-06-13 2012-10-17 大蔵製薬株式会社 抗真菌剤の医薬組成物
WO2009008006A2 (en) 2007-07-06 2009-01-15 Lupin Limited Pharmaceutical compositions for gastrointestinal drug delivery
KR100937625B1 (ko) 2007-08-10 2010-01-20 주식회사 제닉 가용성 웹 공극필름 및 이의 제조방법
US9186640B2 (en) 2007-08-28 2015-11-17 Pepsico, Inc. Delivery and controlled release of encapsulated lipophilic nutrients
EP2583669A1 (en) * 2007-10-10 2013-04-24 Rubicon Research Private Limited Taste-masked orally disintegrating tablets of memantine hydrochloride
JP5249941B2 (ja) 2007-10-12 2013-07-31 株式会社龍角散 薬服用粒状ゼリー飲料及びその製造方法
US20090104251A1 (en) 2007-10-22 2009-04-23 Sensient Flavors Inc. Heat stable microcapsules and methods for making and using the same
US8563066B2 (en) * 2007-12-17 2013-10-22 New World Pharmaceuticals, Llc Sustained release of nutrients in vivo
CN101951923B (zh) 2007-12-20 2013-10-30 N.V.努特里奇亚 含核苷酸/核苷的液态产品
CN101938992B (zh) 2008-02-06 2013-07-10 东英吉利大学 用于辅助吞咽的组合物及方法
KR101449785B1 (ko) 2008-04-21 2014-10-14 오토노미, 인코포레이티드 귀 질환 및 병태를 치료하기 위한 귀 조제물
US8791064B2 (en) 2008-04-24 2014-07-29 Technion Research And Development Foundation Ltd. Beta-lactoglobulin-polysaccharide nanoparticles for hydrophobic bioactive compounds
GB0813929D0 (en) 2008-07-30 2008-09-03 Glaxo Group Ltd Novel method
US9414615B2 (en) * 2010-01-18 2016-08-16 PepciCo, Inc. Gel-based compositions and methods of making same

Similar Documents

Publication Publication Date Title
JP2013537891A5 (enExample)
AU2024227357A1 (en) Ganaxolone For Use In Treating Genetic Epileptic Disorders
JP2014528474A5 (enExample)
JP5589130B1 (ja) 結晶及び該結晶を含有してなる医薬製剤
FI3504187T3 (fi) Pridopidiinin käyttö toiminnallisen heikkenemisen hoitoa varten
JP2015524444A5 (enExample)
Saini et al. Motor and non-motor symptoms, drugs, and their mode of action in Parkinson’s disease (PD): a review
JP6456533B2 (ja) ロキソプロフェン含有外用剤組成物
JP2008044951A5 (enExample)
JP2012530723A5 (enExample)
Lehrer-Graiwer et al. GBT440, a potent anti-sickling hemoglobin modifier reduces hemolysis, improves anemia and nearly eliminates sickle cells in peripheral blood of patients with sickle cell disease
CN107951869A (zh) 含有大麻二酚的药物制剂及其应用
JP2013541583A (ja) 組み合わせ組成物
JP5842058B2 (ja) 自閉症の治療における使用のためのクレンブテロール
CN118078835A (zh) 用于夜间尿频的治疗剂
TW201034674A (en) Uses of NK receptor antagonists
CN102716120B (zh) (3r)-去-o-甲基毛狄泼老素在制备预防或治疗抑郁症的药物中的用途
Garnock-Jones Diclofenac potassium powder for oral solution: a review of its use in patients with acute migraine
JP6454436B1 (ja) ペマフィブラートを含有する医薬
CN115607545B (zh) 依达拉奉在自闭症谱系障碍治疗中的应用
JP2011246451A (ja) 抗炎症剤組成物
JP6178058B2 (ja) 抗炎症及び/又は抗ヒスタミン剤組成物
CN117715633A (zh) 用于治疗covid-19、自身免疫性疾病或细胞因子风暴反应的利多卡因或阿替卡因
CN115803040A (zh) 用于处理covid-19和相关病症的组合物
WO2014057180A1 (fr) Utilisation d'un melange argon/xenon pour prevenir ou traiter les consequences neurologiques d'un choc septique